Phibro Animal Health Corporation

NASDAQ:PAHC

Drug Manufacturers - Specialty & Generic

Healthcare
$35.57 +1.23%

+$0.38 today

Market cap
$1.44B
Beta
0.46
P/E (TTM)
13.3
EPS (TTM)
$2.35
Dividend yield
1.54%
52W Low $23.57High $60.08

Volume 0.11M

Average 0.37M

PAHC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Phibro Animal Health CorporationNASDAQ: PAHC

Net Income · Q3 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q3 FY2026 net income of $24.02M rose 15.1% year over year, behind the +199.6% change in trailing-twelve-month net income. Sequentially, it fell 12.5% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.

Context

  • Net income amounted to 3.7% of revenue in FY2025, up 3.5 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $125.83M (+160.7%) for the fiscal year ending Jun 2026, a slowdown from the +1897.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.02M-12.5% QoQ
Last fiscal yearJun 2025
$48.26M+1897.7% YoY
LTMMar 2026
$95.23M+199.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.1%+69.5%+54.4 pp
1 year+1897.7%+160.7%-1737.0 pp
3-year CAGR-0.6%+49.0%+49.6 pp
5-year CAGR+32.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
48.26M USD
Year-over-year change
+1897.7%
4-year CAGR
-2.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PAHC compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +199.6% is the highest of 6, against a peer median of -94.6%.
  • Net income amounts to 6.3% of revenue for PAHC, versus a peer median of 6.4%.
PAHC Competitors
Net Income for PAHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
ZTSZoetis Inc.LTM Jun 2026$2.62B USD-0.2%+8.2%27.5%
ELANElanco Animal Health IncorporatedLTM Sep 2026$103M USD-386.1%+43.8%2.0%
PAHCPhibro Animal Health CorporationLTM Mar 2026$95.23M USD+199.6%-0.6%6.3%
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥82.97M CNY-715.9%—71.3%
NEOGNeogen CorporationLTM Aug 2026$56.14M USD-94.6%-29.8%6.4%
Peer median (excluding PAHC) —-94.6%+8.0%6.4%

Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income54.39M49.18M32.61M2.42M48.26M
Depreciation & Amortization31.89M32.71M34.01M36.18M45.61M
Deferred Income Tax(2.18M)(806K)(2.84M)(7.84M)(4.88M)
Stock-Based Compensation1.13M00475K717K
Change in Working Capital(29.87M)(44.64M)(41.13M)33.11M(21.56M)
Accounts Receivables(18.21M)(23.63M)5.34M(8.68M)(55.21M)
Inventory(12.5M)(47M)(11.22M)2.64M(44.29M)
Accounts Payables3.18M26.36M(22.83M)12M45.56M
Other Working Capital(2.34M)(373K)(12.42M)27.15M32.39M
Other Non-Cash Items(7.04M)(4.79M)(9.34M)23.25M11.98M
Operating Cash Flow48.31M31.65M13.31M87.59M80.12M
Capital Expenditures(29.32M)(37.04M)(51.79M)(41.24M)(38.29M)
Acquisitions (Net)29.32M(13.51M)0(3.28M)(286.53M)
Purchases of Investments(74M)(64.1M)(40M)(65.52M)(14M)
Sales of Investments86M91.45M17M61.52M49M
Other Investing Activities(30.58M)620K776K326K1.13M
Investing Cash Flow(18.58M)(22.58M)(74.02M)(48.19M)(288.69M)
Debt Repayment5.38M40.63M42.69M12.71M235.99M
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid(19.43M)(19.44M)(19.44M)(19.44M)(19.45M)
Other Financing Activities(2.94M)(4.84M)3.74M(31K)(9.4M)
Financing Cash Flow(17M)16.34M26.99M(6.77M)207.13M
Effect of Forex Changes1.14M(1.37M)754K(3.3M)(1.14M)
Net Change in Cash13.87M24.04M(32.97M)29.33M(2.57M)
Free Cash Flow18.99M(5.4M)(38.48M)46.36M41.83M

Phibro Animal Health Corporation

NASDAQ:PAHC

Intrinsic Alpha fair value

Locked

Current Price

$35.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.